
    
      This is a Phase 2B randomized, double-blind, placebo-controlled, multiple dose, multicenter
      study designed to evaluate the efficacy, safety and microbiome alterations associated with
      two dose levels of SER-287, after pre-treatment with vancomycin, in adult subjects, age
      18-80, with active mild-to-moderate ulcerative colitis (UC).
    
  